Podium to Practice: Chicago 2025 – GU: CheckMate 901

Podium to Practice: Chicago 2025 – GU: CheckMate 901

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sebastien Hotte

Icon Chair Speaker

Speakers

Dr. Nimira Alimohamed

Dr. Maria Jiang

Studies / Trials Discussed

4500 – Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.

This program has been made possible through unrestricted support from Ipsen.

Studies/trials discussed:

4500 – Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
Tagged